logo
NasdaqGM:ANIP logo

ANI Pharmaceuticals Community

NasdaqGM:ANIP Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

ANIP logo
ANI Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts

ILUVIEN And YUTIQ Will Expand Market Use After Positive Trial Results In 2025

Key Takeaways Acquisition of Alimera and expansion in ophthalmology strengthen ANI's portfolio, boosting future sales and market presence. New product launches and clinical trial successes poised to drive revenue growth and improve net margins.
View narrative
US$81.88
FV
26.5% undervalued intrinsic discount
12.85%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
5 days ago author updated this narrative